<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">AAPS PharmSci</journal-id><journal-id journal-id-type="pmc-domain-id">989</journal-id><journal-id journal-id-type="pmc-domain">pharmsci</journal-id><journal-title-group><journal-title xml:lang="en">AAPS PharmSci</journal-title></journal-title-group><issn pub-type="epub">1522-1059</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2751032</article-id><article-id pub-id-type="pmcid-ver">PMC2751032.1</article-id><article-id pub-id-type="pmcaid">2751032</article-id><article-id pub-id-type="pmcaiid">2751032</article-id><article-id pub-id-type="pmid">11741234</article-id><article-id pub-id-type="doi">10.1208/ps020218</article-id><article-id pub-id-type="publisher-id">220109</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kulkarni</surname><given-names initials="SG">Swarupa G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pegram</surname><given-names initials="AA">Anita A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Smith</surname><given-names initials="PC">Philip C.</given-names></name><address><email>pcs@email.unc.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Wake Forest University Medical Center, Winston Salem, North Carolina USA </aff><aff id="Aff2"><label>2</label>Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina-Chapel Hill, 27599 Chapel Hill, North Carolina USA </aff></contrib-group><pub-date pub-type="collection"><month>6</month><year>2000</year></pub-date><pub-date pub-type="epub"><day>22</day><month>6</month><year>2000</year></pub-date><volume>2</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">181863</issue-id><fpage>109</fpage><lpage>116</lpage><history><date date-type="received"><day>15</day><month>3</month><year>2000</year></date><date date-type="accepted"><day>7</day><month>6</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>06</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>14</day><month>10</month><year>2009</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2013-04-03 19:55:29.450"><day>03</day><month>04</month><year>2013</year></date></event></pub-history><permissions><copyright-statement>&#169; American Association of Pharmaceutical Scientists 2000</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12248_2008_Article_220109.pdf"/><abstract xml:lang="en"><p>Drug treatment poses a therapeutic challenge in cystic fibrosis (CF) because the disposition of a number of drugs is altered in CF. Enhanced clearance of acetaminophen (APAP) and indocyanine green (ICG) have previously been reported in CF patients. The objective of the current study was to investigate if the CF-knockout mouse model (cftr<sup>m1UNC</sup>) shows altered pharmacokinetics similar to those seen in CF patients using the 2 model compounds APAP and ICG. Clearance (CL/F) of APAP and renal (CL<sub>R</sub>) and formation (CL<sub>f</sub>) clearance of acetaminophen glucuronide (AG) and acetaminophen sulfate (AS) were determined in CF-knockout mice following administration of APAP (50 mg/kg, intraperitoneal). CL<sub>R</sub> of AS was 19.5 and 12.9 (mL/min per kg) and CL<sub>f</sub> of AS was 10.4 and 6.7 mL/min per kg for homozygous and heterozygous males, respectively, which was significantly different between groups. CL<sub>R</sub> of AG was 6.3 and 4.8 mL/min per kg and CL<sub>f</sub> of AG was 9.6 and 8.9 mL/min per kg for homozygous and heterozygous males, respectively, although not reaching statistical significance. No significant differences were noted in either Cl<sub>R</sub> or CL<sub>f</sub> of AG and AS in female CF mice. Plasma concentrations of ICG (10 mg/kg, intravenous) were determined over 0 to 15 minutes. Homozygous females showed a higher apparent volume of distribution (96 mL/kg) relative to heterozygous females (72 mL/kg). Similar to CF patients, a trend toward a lower C<sub>max</sub> was noted in homozygous male and female mice. However, contrary to human data, no significant differences in CL of ICG were noted. These results suggest that the CF-knockout mice have potential as a model for studying altered drug disposition in CF patients.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; American Association of Pharmaceutical Scientists 2000</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>